Jeffrey A Sklar1, Soren M White. 1. Center For Aesthetic Dermatology, Woodbury, New York 11797, USA. jsklar2426@aol.com
Abstract
BACKGROUND: Calcium hydroxylapatite has been used in various forms in facial reconstruction, radiologic procedures, stress urinary incontinence, and vocal cord problems. OBJECTIVES: To demonstrate the effectiveness and safety of calcium hydroxylapatite as an aesthetic soft tissue filler. METHODS: Sixty-four consecutive patients from two centers were treated with Radiance FN over a 6-month period in various facial areas. RESULTS: All patients showed clinical improvement. Side effects were minimal, consisting of mild bruising or swelling. There was a low incidence of complications, consisting of lip nodularity and tear trough overcorrection. CONCLUSION: Radiance FN offers a new alternative as a deep soft tissue filler. Aesthetic correction was immediate with little downtime. Patient satisfaction was high with minimal side effects. Lip nodularity was the main complication. Correction in all patients has persisted to date, with our longest follow-up being 6 months.
BACKGROUND:Calcium hydroxylapatite has been used in various forms in facial reconstruction, radiologic procedures, stress urinary incontinence, and vocal cord problems. OBJECTIVES: To demonstrate the effectiveness and safety of calcium hydroxylapatite as an aesthetic soft tissue filler. METHODS: Sixty-four consecutive patients from two centers were treated with Radiance FN over a 6-month period in various facial areas. RESULTS: All patients showed clinical improvement. Side effects were minimal, consisting of mild bruising or swelling. There was a low incidence of complications, consisting of lip nodularity and tear trough overcorrection. CONCLUSION: Radiance FN offers a new alternative as a deep soft tissue filler. Aesthetic correction was immediate with little downtime. Patient satisfaction was high with minimal side effects. Lip nodularity was the main complication. Correction in all patients has persisted to date, with our longest follow-up being 6 months.